Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
08 April 2026The European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance
The European Commission DG HERA has announced a €30 million EU4Health investment, managed by KfW, to support CARB-X and GARDP in strengthening the global response to antimicrobial resistance (AMR). The funding aims to create a fully integrated innovation pipeline, with CARB-X focusing on early-stage R&D (antibiotics, vaccines, diagnostics, preventatives) and GARDP advancing late-stage clinical development, […]
Read more... -
01 April 2026Accuracy of rapid microcapillary direct antibiotic susceptibility testing for urine samples collected with bacteriostatic boric acid from patients with suspected urinary tract infection
This study evaluated a rapid microcapillary direct-from-urine (RMD) antibiotic susceptibility testing (AST) method for patients with suspected urinary tract infections (UTIs), including samples preserved with boric acid. Key findings: High accuracy: RMD AST showed ~97% concordance with standard reference methods. Fast results: Average turnaround time was ~5.9 hours, significantly faster than conventional AST. Robust performance: […]
Read more... -
23 March 2026Nanomotion-enabled ultra-rapid antibiotic susceptibility testing with magnetic bead-based pathogen enrichment for accelerated sepsis diagnostics
A new diagnostic approach significantly speeds up antimicrobial susceptibility testing (AST) for serious infections like sepsis. Traditional methods rely on blood cultures and take 48–72 hours, often forcing doctors to use broad-spectrum antibiotics. This new method combines rapid bacterial enrichment from blood with nanomotion detection and AI analysis, delivering highly accurate results (94–98%) in as […]
Read more...
More news related to Smart innovation
